Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women

被引：10

作者：

Vogelvang, TE

Mijatovic, V

Kenemans, P

Schalkwijk, CG

van der Mooren, MJ

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Obstet & Gynecol, ICaR, NL-1007 MB Amsterdam, Netherlands

[2] Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, ICaR, NL-1007 MB Amsterdam, Netherlands

[3] Vrije Univ Amsterdam, Med Ctr, Project Aging Women, NL-1007 MB Amsterdam, Netherlands

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 94卷 / 09期

关键词：

D O I：

10.1016/j.amjcard.2004.07.099

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We investigated the 12-week effects of 3 doses of HMR 3339, a novel selective estrogen receptor modulator, in comparison with raloxifene and placebo, on plasma concentrations of C-reactive protein in 96 healthy postmenopausal women. A dose-dependent reduction in C-reactive protein was observed, the largest reduction with HMR 3339 50 mg. (C) 2004 by Excerpta Medica, Inc.

引用

页码：1205 / 1208

页数：4

共 50 条

[1] HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women
Vogelvang, TE
Mijatovic, V
Kenemans, P
Teerlink, T
van der Mooren, MJ
FERTILITY AND STERILITY, 2004, 82 (06) : 1540 - 1549
[2] HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo-controlled study in postmenopausal women
Vogelvang, TE
Leurs, JR
Mijatovic, V
Willemse, J
Van der Mooren, MJ
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (05) : 1090 - 1092
[3] The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: A randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women
Vogelvang, TE
Mijatovic, V
Kenemans, P
Emeis, JJ
Heijst, JA
van der Mooren, MJ
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 193 (04) : 1384 - 1394
[4] Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women
Verhoeven, Marieke O.
Teerlink, Tom
Kenemans, Peter
Vogelvang, Tatjana E.
van der Mooren, Marius J.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2007, 14 (02): : 235 - 242
[5] Effect Of Abdominal And Total Fat On C-reactive Protein Levels In Postmenopausal Women
Wright, Jennifer
Stanescu, Claudia I.
Cussler, Ellen C.
Williams, Daniel P.
Going, Scott B.
Lohman, Timothy G.
Bartell-Weiss, Lauren
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2005, 37 : S303 - S304
[6] Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women
Herrington, DM
Pusser, BE
Riley, WA
Thuren, TY
Brosnihan, KB
Brinton, EA
MacLean, DB
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (06) : 1606 - 1612
[7] Augmentation Index is Not Related to C-Reactive Protein in Healthy Postmenopausal Women
Roy, Matthew S.
Edwards, David G.
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2006, 38 (05): : S186 - S186
[8] Endogenous sex hormones and C-reactive protein in healthy postmenopausal women
Stoerk, S.
Bots, M. L.
Grobbee, D. E.
van der Schouw, Y. T.
JOURNAL OF INTERNAL MEDICINE, 2008, 264 (03) : 245 - 253
[9] Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: Comparison between oral and transdermal administration of estrogen
Modena, MG
Bursi, F
Fantini, G
Cagnacci, A
Carbonieri, A
Fortuna, A
Rossi, R
AMERICAN JOURNAL OF MEDICINE, 2002, 113 (04): : 331 - 333
[10] A new selective estrogen receptor modulator HMR-3339 fully corrects bone alterations induced by ovariectomy in adult rats
Ammann, P
Bourrin, S
Brunner, F
Meyer, JM
Clément-Lacroix, P
Baron, R
Gaillard, M
Rizzoli, R
BONE, 2004, 35 (01) : 153 - 161

← 1 2 3 4 5 →